文献速递骨软组织肉瘤与黑色素瘤

可切除III期黑色素瘤新辅助伊匹木单抗联合纳武利尤单抗最优剂量方案探索(OpACIN-neo)

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2019-05-31

OpACIN-neo是一项多中心、开放标签、2期随机对照试验,纳入89例可切除III期黑色素瘤患者,随机分配至三种新辅助伊匹木单抗联合纳武利尤单抗方案。主要终点为12周内3-4级免疫相关毒性和6周时影像学客观缓解及病理缓解。结果显示B组(伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg,每3周一次,共2周期)毒性较低且病理缓解率高,可能适合更广泛的临床使用。

要点

  • B组3-4级免疫相关毒性为20%,低于A组的40%和C组的50%。
  • B组病理缓解率为77%,A组80%,C组65%。
  • B组方案(伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg)毒性较低且疗效相当,可能适合更广泛临床使用。

核心结论

  • OpACIN-neo确定了一个可耐受的新辅助剂量方案(B组:伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg,每3周一次,共2周期),该方案在较高比例患者中诱导病理缓解,可能适合更广泛的临床使用。

研究设计与样本

  • 多中心、开放标签、2期随机对照试验,纳入89例可切除III期黑色素瘤患者,随机分配至三种新辅助治疗方案。
  • A组:伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg,每3周一次,共2周期;B组:伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg,每3周一次,共2周期;C组:伊匹木单抗3 mg/kg每3周一次共2周期,随后纳武利尤单抗3 mg/kg每2周一次共2周期。
  • 主要终点为12周内3-4级免疫相关毒性比例和6周时影像学客观缓解及病理缓解比例。

主要发现

  • 12周内3-4级免疫相关不良事件:A组12/30(40%),B组6/30(20%),C组13/26(50%)。
  • 影像学客观缓解:A组19/30(63% [95% CI 44-80]),B组17/30(57% [37-75]),C组9/26(35% [17-56])。
  • 病理缓解:A组24/30(80% [61-92]),B组23/30(77% [58-90]),C组17/26(65% [44-83])。

临床怎么用

  • B组方案(伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg,每3周一次,共2周期)毒性较低且病理缓解率高,可能适合更广泛的临床使用。
  • 当更成熟数据确认这些早期观察结果后,该方案应在随机3期研究中与辅助治疗(目前III期黑色素瘤的标准系统治疗)进行比较。

局限性

  • C组因严重不良事件根据数据安全监查委员会建议提前终止入组。
  • 研究为2期试验,样本量有限,需更成熟数据和3期研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outcome of patients with macroscopic stage III melanoma is poor. Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule induced pathological responses in a high proportion of patients in two small independent early-phase trials, and no patients with a pathological response have relapsed after a median follow up of 32 months. However, toxicity of the standard ipilimumab plus nivolumab dosing schedule was high, preventing its broader clinical use. The aim of the OpACIN-neo trial was to identify a dosing schedule of ipilimumab plus nivolumab that is less toxic but equally effective. METHODS: OpACIN-neo is a multicentre, open-label, phase 2, randomised, controlled trial. Eligible patients were aged at least 18 years, had a WHO performance status of 0-1, had resectable stage III melanoma involving lymph nodes only, and measurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1. Patients were enrolled from three medical centres in Australia, Sweden, and the Netherlands, and were randomly assigned (1:1:1), stratified by site, to one of three neoadjuvant dosing schedules: group A, two cycles of ipilimumab 3 mg/kg plus nivolumab 1 mg/kg once every 3 weeks intravenously; group B, two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg once every 3 weeks intravenously; or group C, two cycles of ipilimumab 3 mg/kg once every 3 weeks directly followed by two cycles of nivolumab 3 mg/kg once every 2 weeks intravenously. The investigators, site staff, and patients were aware of the treatment assignment during the study participation. Pathologists were masked to treatment allocation and all other data. The primary endpoints were the proportion of patients with grade 3-4 immune-related toxicity within the first 12 weeks and the proportion of patients achieving a radiological objective response and pathological response at 6 weeks. Analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02977052, and is ongoing with an additional extension cohort and to complete survival analysis. FINDINGS: Between Nov 24, 2016 and June 28, 2018, 105 patients were screened for eligibility, of whom 89 (85%) eligible patients were enrolled and randomly assigned to one of the three groups. Three patients were excluded after randomisation because they were found to be ineligible, and 86 received at least one dose of study drug; 30 patients in group A, 30 in group B, and 26 in group C (accrual to this group was closed early upon advice of the Data Safety Monitoring Board on June 4, 2018 because of severe adverse events). Within the first 12 weeks, grade 3-4 immune-related adverse events were observed in 12 (40%) of 30 patients in group A, six (20%) of 30 in group B, and 13 (50%) of 26 in group C. The difference in grade 3-4 toxicity between group B and A was -20% (95% CI -46 to 6; p=0·158) and between group C and group A was 10% (-20 to 40; p=0·591). The most common grade 3-4 adverse events were elevated liver enzymes in group A (six [20%)]) and colitis in group C (five [19%]); in group B, none of the grade 3-4 adverse events were seen in more than one patient. One patient (in group A) died 9·5 months after the start of treatment due to the consequences of late-onset immune-related encephalitis, which was possibly treatment-related. 19 (63% [95% CI 44-80]) of 30 patients in group A, 17 (57% [37-75]) of 30 in group B, and nine (35% [17-56]) of 26 in group C achieved a radiological objective response, while pathological responses occurred in 24 (80% [61-92]) patients in group A, 23 (77% [58-90]) in group B, and 17 (65% [44-83]) in group C. INTERPRETATION: OpACIN-neo identified a tolerable neoadjuvant dosing schedule (group B: two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg) that induces a pathological response in a high proportion of patients and might be suitable for broader clinical use. When more mature data confirm these early observations, this schedule should be tested in randomised phase 3 studies versus adjuvant therapies, which are the current standard-of-care systemic therapy for patients with stage III melanoma. FUNDING: Bristol-Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019. PMID: 31160251. doi:10.1016/S1470-2045(19)30151-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。